Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.
作者： Bénédicte FAUVEL , Aziz Yasri
DOI: 10.4161/MABS.29089
关键词:
摘要: Approximately 30 therapeutic monoclonal antibodies have already been approved for cancers and inflammatory diseases, continue to be one of the fastest growing classes molecules. Because aberrant signaling by receptor tyrosine kinases (RTKs) is a commonly observed factor in cancer, most subclasses RTKs are being extensively studied as potential targets treating malignancies. The first two that targeted antibody therapy, with five currently marketed antibodies, growth receptors EGFR HER2. However, due systemic side effects, refractory patients development drug resistance, these treatments challenged emerging therapeutics. This review examines current therapies against RTKs. After an analysis agents approved, we present clinical target Finally, highlight promising new oncological antibody-based therapy.
sci-hub.se 参考文章(155)
Jennifer E Hardingham, Amanda Townsend, Timothy J Price, Omar Mohyieldin, Shalini Sree Kumar, Matthew Borg, KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model. Gastrointestinal cancer research : GCR. ,vol. 7, pp. 23- 26 ,(2014)
S. Kahlert, H.J. Stemmler, V. Heinemann, M. Untch, H. Menzel, C. Salat, G. Ledderose, H. Lindhofer, G. Konecny, H. Sauer, H.J. Kolb, Combined Treatment of Metastatic Breast Cancer (MBC) by High-dose Chemotherapy (HDCT) and Bispecific Antibodies: A Pilot Study Anticancer Research. ,vol. 25, pp. 3047- 3054 ,(2005)
Sylwia Chocholska, Paweł Krawczyk, Janusz Milanowski, Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer. Annales Universitatis Mariae Curie-Skłodowska. ,vol. 58, pp. 113- 117 ,(2003)
Heather A Wakelee, Yelena Krupitskaya, Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Current opinion in investigational drugs. ,vol. 10, pp. 597- 605 ,(2009)
Rodrigo Dienstmann, Josep Tabernero, None, Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Current opinion in investigational drugs. ,vol. 11, pp. 1434- 1441 ,(2010)
Arne Östman, Carl‐Henrik Heldin, PDGF receptors as targets in tumor treatment. Advances in Cancer Research. ,vol. 97, pp. 247- 274 ,(2007) , 10.1016/S0065-230X(06)97011-0
Jorge A. Garcia, Gary R. Hudes, Toni K. Choueiri, Walter M. Stadler, Laura S. Wood, Jayne Gurtler, Shailender Bhatia, Adarsh Joshi, Rebecca R. Hozak, Yihuan Xu, Jonathan D. Schwartz, John A. Thompson, A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy Cancer. ,vol. 120, pp. 1647- 1655 ,(2014) , 10.1002/CNCR.28634
Haim Werner, Derek LeRoith, The Role of the Insulin-like Growth Factor System in Human Cancer Advances in Cancer Research. ,vol. 68, pp. 183- 223 ,(1996) , 10.1016/S0065-230X(08)60354-1
Jonathan M. Bock, Shyh-Min Huang, Paul M. Harari, Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research. ,vol. 59, pp. 1935- 1940 ,(1999)
Jonathan D. Schwartz, Eric K. Rowinsky, Hagop Youssoufian, Bronislaw Pytowski, Yan Wu, Vascular endothelial growth factor receptor-1 in human cancer Cancer. ,vol. 116, pp. 1027- 1032 ,(2010) , 10.1002/CNCR.24789